BTS statement on malignant mesothelioma in the UK, 2007.
Wexham Park Hospital, Slough, UK. john.wiggins@hwph-tr.nhs.uk
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001194:Asbestos / Q000633:toxicity; D015415:Biomarkers / Q000097:blood; D017322:Clinical Trials, Phase II as Topic; D003142:Communication; D003937:Diagnosis, Differential; D003952:Diagnostic Imaging / Q000379:methods; D004185:Disability Evaluation; D004417:Dyspnea / Q000517:prevention & control; D006297:Health Services Accessibility / Q000458:organization & administration; D006801:Humans; D008654:Mesothelioma / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D009720:Nurse Clinicians / Q000706:statistics & numerical data; D024802:Nurse's Role; D009784:Occupational Diseases / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D010146:Pain / Q000517:prevention & control; D010166:Palliative Care / Q000379:methods; D010353:Patient Education as Topic; D018802:Patient-Centered Care; D010415:Pensions; D010534:Peritoneal Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D010808:Physical Examination; D010996:Pleural Effusion / Q000628:therapy; D010997:Pleural Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D011379:Prognosis; D012944:Social Support; D016019:Survival Analysis; D014942:Workers' Compensation / Q000191:economics / Q000331:legislation & jurisprudence
D000970:Antineoplastic Agents; D015415:Biomarkers; D001194:Asbestos